Case report: Durable response of immuno-chemotherapy targeting a rare ROS1 fusion-positive extensive-stage SCLC patient after primary resistance to crizotinib
We hypothesize that ROS1 fusion may not function as an oncogenic driver alteration in ES-SCLC. Immuno-chemotherapy, not ROS1-TKIs, might provide superior efficacy in ES-SCLC patients with ROS1 fusion.
Authors
- Yong Zhu (ORCID: https://orcid.org/0000-0002-0772-2474)
- Huiting Peng
- Min Qiu (ORCID: https://orcid.org/0000-0002-2297-3351)
- Zehuai Guo (ORCID: https://orcid.org/0000-0002-7085-9502)
- Jieheng Lin
- Sisi Wang (ORCID: https://orcid.org/0000-0002-3665-7835)
- Yang Cao (ORCID: https://orcid.org/0000-0002-3695-3992)
- Yesong Guo
- Siqi Wu (ORCID: https://orcid.org/0000-0003-1927-6018)
- Peiwen Guo
Institutions
- Guangzhou University of Chinese Medicine (CN)
- Hubei University of Chinese Medicine (CN)
- Shantou University (CN)
- Cancer Hospital of Shantou University Medical College (CN)
- First Affiliated Hospital of Guangzhou University of Chinese Medicine (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-04-29
- DOI
- https://doi.org/10.3389/fphar.2025.1522542
- Citations
- 2
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- National Natural Science Foundation of China
- Guangdong Science and Technology Department
- Basic and Applied Basic Research Foundation of Guangdong Province